Integer Holdings Co. (NYSE:ITGR) Stock Position Raised by Azzad Asset Management Inc. ADV

Azzad Asset Management Inc. ADV grew its stake in shares of Integer Holdings Co. (NYSE:ITGR) by 7.9% in the 1st quarter, HoldingsChannel reports. The firm owned 7,772 shares of the medical equipment provider’s stock after acquiring an additional 566 shares during the quarter. Azzad Asset Management Inc. ADV’s holdings in Integer were worth $907,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Vanguard Group Inc. boosted its position in shares of Integer by 0.4% in the third quarter. Vanguard Group Inc. now owns 3,843,992 shares of the medical equipment provider’s stock worth $301,484,000 after buying an additional 15,300 shares during the period. abrdn plc grew its stake in Integer by 0.6% during the 4th quarter. abrdn plc now owns 520,646 shares of the medical equipment provider’s stock valued at $51,586,000 after acquiring an additional 3,013 shares in the last quarter. Congress Asset Management Co. MA increased its holdings in shares of Integer by 7.5% in the 1st quarter. Congress Asset Management Co. MA now owns 453,260 shares of the medical equipment provider’s stock valued at $52,886,000 after purchasing an additional 31,736 shares during the period. Charles Schwab Investment Management Inc. lifted its position in shares of Integer by 0.9% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 382,936 shares of the medical equipment provider’s stock worth $37,941,000 after purchasing an additional 3,504 shares in the last quarter. Finally, Tributary Capital Management LLC boosted its holdings in shares of Integer by 1.2% during the first quarter. Tributary Capital Management LLC now owns 285,677 shares of the medical equipment provider’s stock worth $33,333,000 after purchasing an additional 3,513 shares during the period. Institutional investors and hedge funds own 99.29% of the company’s stock.

Insider Activity at Integer

In other news, Director James F. Hinrichs sold 9,603 shares of Integer stock in a transaction dated Friday, May 24th. The stock was sold at an average price of $122.44, for a total value of $1,175,791.32. Following the transaction, the director now directly owns 7,424 shares in the company, valued at $908,994.56. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, EVP John A. Harris sold 1,521 shares of the company’s stock in a transaction on Tuesday, June 4th. The shares were sold at an average price of $120.44, for a total transaction of $183,189.24. Following the completion of the transaction, the executive vice president now directly owns 4,922 shares in the company, valued at approximately $592,805.68. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director James F. Hinrichs sold 9,603 shares of the firm’s stock in a transaction on Friday, May 24th. The stock was sold at an average price of $122.44, for a total transaction of $1,175,791.32. Following the completion of the sale, the director now owns 7,424 shares in the company, valued at $908,994.56. The disclosure for this sale can be found here. In the last three months, insiders have sold 17,936 shares of company stock worth $2,130,937. 2.00% of the stock is owned by insiders.

Analyst Ratings Changes

Several research analysts have weighed in on the stock. Truist Financial assumed coverage on shares of Integer in a research note on Wednesday, May 15th. They issued a “buy” rating and a $137.00 price objective on the stock. CL King assumed coverage on Integer in a report on Thursday, March 14th. They set a “buy” rating and a $137.00 price objective for the company. Benchmark restated a “buy” rating and issued a $130.00 target price on shares of Integer in a research note on Friday, May 10th. Bank of America raised Integer from a “neutral” rating to a “buy” rating and upped their target price for the stock from $105.00 to $135.00 in a research report on Monday, April 15th. Finally, KeyCorp lifted their price target on Integer from $123.00 to $139.00 and gave the company an “overweight” rating in a report on Tuesday, April 9th. Three research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $128.00.

Integer Stock Down 1.4 %

Shares of ITGR traded down $1.58 during trading hours on Wednesday, hitting $114.17. 23,574 shares of the company were exchanged, compared to its average volume of 319,559. The firm’s 50 day moving average is $116.82 and its 200-day moving average is $110.69. The company has a debt-to-equity ratio of 0.76, a quick ratio of 2.01 and a current ratio of 3.32. Integer Holdings Co. has a 52 week low of $69.40 and a 52 week high of $123.99. The company has a market cap of $3.82 billion, a PE ratio of 40.05, a PEG ratio of 1.71 and a beta of 1.11.

Integer (NYSE:ITGR) last announced its earnings results on Thursday, April 25th. The medical equipment provider reported $1.14 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.12 by $0.02. Integer had a return on equity of 11.25% and a net margin of 6.01%. The firm had revenue of $414.80 million during the quarter, compared to analysts’ expectations of $412.78 million. During the same quarter in the prior year, the business earned $0.87 earnings per share. The company’s revenue was up 9.5% on a year-over-year basis. On average, equities research analysts forecast that Integer Holdings Co. will post 5.27 EPS for the current fiscal year.

About Integer

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.